The session, hosted by Maria Isabel Leite and Nils Erik Gilhus, presented clinical data on the BeatMG study, a Phase II randomised, double-blind, placebo-controlled study assessing the efficacy of rituximab in treating gMG with anti-acetylcholine receptor (AChR) antibodies.